The global anti-viral therapies market was valued at $38,316.5 million in 2018, and is projected to reach $46,213.4 million by 2026 registering a CAGR of 2.4% from 2019 to 2026. Antiviral drugs belong to the class of medicines, which are used for treating viral infections, such as HIV, herpes, hepatitis, and influenza. These drugs are generally administered in the form of vaccines. In addition, most of these drugs are used for specific viral infections, while a few (broad-spectrum antiviral drugs) are effective against a wide range of viruses.

The global antiviral therapies market is majorly driven by increase in the incidence rate of viral infections. In addition, rise in R&D activities and development of newer & advanced formulations, such as vaccines and combination therapy along with pipeline products, are expected to fuel the market growth. However, high cost involved in the treatment and rise in demand for alternative medicines such as naturopathy and homeopathy are likely to restrain the market growth. On the contrary, development and approvals of combination therapies and growth opportunities in the emerging economies of Asia-Pacific and LAMEA regions are anticipated to provide numerous opportunities for the market growth during the forecast period.

The global antiviral therapies market is segmented on the basis of application, type, mechanism of action, and region. Based on application, the market is categorized into HIV, hepatitis, herpes, influenza, and other viral diseases. On the basis of type, it is classified into generic drugs and branded drugs. By mechanism of action, it is divided into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

? This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2026, which assists to identify the prevailing market opportunities.
? An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
? A comprehensive analysis of the factors that drive and restrain the growth of the global clinical nutrition market is provided.
? An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS
By Application
- HIV
- Hepatitis
- Herpes Virus
- Influenza
- Other Applications
By Type
- Generic Drugs
- Branded Drugs
By Mechanism of Action
- Nucleotide Polymerase Inhibitor
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Others
By Region
- North America
o U.S.
o Canada
o Mexico
- Europe
o Germany
o France
o Spain
o Italy
o UK
o Rest of Europe
- Asia-Pacific
o Japan
o India
o China
o Australia
o South Korea
o Rest of Asia-Pacific
- LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
KEY MARKET PLAYERS
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, GlaxoSmithKline
- Bristol-Myers-Squibb
- Abbott Laboratories
- AstraZeneca plc
- AbbVie Inc.
- Aurobindo Pharma Limited
- Johnson & Johnson
- Merck & Co., Inc